Skip to main content
SpringerLink
Log in

Postchemotherapy Retroperitoneal Lymph Node Dissection in Advanced Germ Cell Tumors of the Testis

  • Living reference work entry
  • First Online:
Urologic Oncology

  • 138 Accesses

Abstract

Postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) plays an integral part of the multimodality treatment in patients with advanced testicular germ cell tumors (TGCT). According to current guidelines and recommendations, PC-RPLND in advanced seminomas with residual tumors >3 cm in diameter is only indicated if a PET scan is performed 6–8 weeks after chemotherapy demonstrates a positive lesion.

In nonseminomatous TGCT, PC-RPLND is indicated for all residual radiographic lesions >1 cm in diameter and with negative or plateauing serum tumor marker concentrations following systemic chemotherapy. Based on the location and the size of the primary and the residual lesion, it has to be decided if a modified or bilateral template resection needs to be performed. Loss of antegrade ejaculation represents the most common long-term complication which can be prevented by a nerve-sparing or modified template resection.

Patients with residual masses <1 cm and an initially good prognosis can undergo active surveillance. PC-RPLND is only indicated in men with intermediate/poor prognosis or a testicular lesions containing teratoma predominantly.

Patients with increasing markers should undergo salvage chemotherapy. Only select patients with elevated markers who are thought to be chemo-refractory might undergo desperation PC-RPLND if all radiographically visible lesions are completely resectable. PC-RPLND requires a complex surgical approach and should be performed in experienced, tertiary referral centers only.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Albers P, Ganz A, Hannig E, Miersch WD, Müller SC. Salvage surgery of chemorefractory germ cell tumors with elevated markers. J Urol. 2000;164:381–4.

    Article  CAS  PubMed  Google Scholar 

  • Albers P, Weissbach L, Krege S, Kliesch S, Hartmann M, Heidenreich A, Walz P, Kuczyk M, Fimmers R, German Testicular Cancer Study Group. Prediction of necrosis after chemotherapy of advanced germ cell tumors: results of a prospective multicenter trial of the German Testicular Cancer Study Group. J Urol. 2004a;171:1835–8.

    Article  PubMed  Google Scholar 

  • Albers P, Höltl W, Heidenreich A, Aharinejad S. Thoracoabdominal resection of retrocrural residual tumors. Aktuelle Urol. 2004b;35:141–50.

    Article  CAS  PubMed  Google Scholar 

  • Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, Horwich A, Laguna MP, Nicolai N, Oldenburg J, European Association of Urology. Guidelines on testicular cancer: 2015 update. Eur Urol. 2015;68(6):1054–68.

    Article  PubMed  Google Scholar 

  • Aprikian AG, Herr HW, Bajorin DF, Bosl GJ. Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors. Cancer. 1994;74:1329–34.

    Article  CAS  PubMed  Google Scholar 

  • Becherer A, De Santis M, Karanikas G, Szabo M, Bokemeyer C, Dohmen BM, Pont J, Dudczak R, Dittrich C, Kletter K. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. Eur J Radiol. 2005;54:284–8.

    Article  PubMed  Google Scholar 

  • Beck SD, Foster RS, Bihrle R, Koch MO, Wahle GR, Donohue JP. Aortic replacement during post-chemotherapy retroperitoneal lymph node dissection. J Urol. 2001;165:1517–20.

    Article  CAS  PubMed  Google Scholar 

  • Beck SD, Foster RS, Bihrle R, Einhorn LH, Donohue JP. Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol. 2005; 23:6149–56.

    Article  PubMed  Google Scholar 

  • Beck SD, Foster RS, Bihrle R, Donohue JP, Einhorn LH. Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor? Cancer. 2007;110:1235–40.

    Article  PubMed  Google Scholar 

  • Berglund R, Lyden S, Tsai E, et al. Nonseminomatous germ cell tumor after chemotherapy with residual mass invading the spine. Eur Urol. 2006;50:372–4.

    Article  PubMed  Google Scholar 

  • Besse B, Grunenwald D, Flechon A, et al. Nonseminomatous germ cell tumors: assessing the need for postchemotherapy contralateral pulmonary resection in patients with ipsilateral complete necrosis. J Thorac Cardiovasc Surg. 2009;137:448–52.

    Article  PubMed  Google Scholar 

  • Cespedes RD, Peretsman SJ. Retroperitoneal recurrences after retroperitoneal lymph node dissection for low-stage nonseminomatous germ cell tumors. Urology. 1999;54:548–52.

    Article  CAS  PubMed  Google Scholar 

  • Cho JS, Kaimakliotis HZ, Cary C, Masterson TA, Beck S, Foster R. Modified retroperitoneal lymph node dissection for post-chemotherapy residual tumour: a long-term update. BJU Int. 2017;120(1):104–8.

    Article  CAS  PubMed  Google Scholar 

  • Collins C, Eckert H. Seminoma of the testis with bone involvement: a report of three cases. Clin Radiol. 1985;36:467–8.

    Article  Google Scholar 

  • Copson E, McKendrick J, Hennessey N, et al. Liver metastases in germ cell cancer: defining a role for surgery after chemotherapy. BJU Int. 2004;94:552–8.

    Article  PubMed  Google Scholar 

  • Daneshmand S, Albers P, Fosså SD, Heidenreich A, Kollmannsberger C, Krege S, Nichols C, Oldenburg J, Wood L. Contemporary management of postchemotherapy testis cancer. Eur Urol. 2012; 62(5):867–76.

    Article  PubMed  Google Scholar 

  • De Santis M, Becherer A, Bokemeyer C, et al. 2-18fluoro-deoxy-d-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update from the multicenter SEMPET trial. J Clin Oncol. 2004;22:1034–9.

    Article  PubMed  Google Scholar 

  • Eggener SE, Carver BS, Loeb S, Kondagunta GV, Bosl GJ, Sheinfeld J. Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors. Cancer. 2007; 109:528–35.

    Article  PubMed  Google Scholar 

  • Ehrlich Y, Yossepovitch O, Kedar D, Baniel J. Distribution of nodal metastases after chemotherapy in nonseminomatous testis cancer: a possible indication for limited dissection. BJU Int. 2006;97:1221–4.

    Article  PubMed  Google Scholar 

  • Ehrlich Y, Brames MJ, Beck SD, Foster RS, Einhorn LH. Long-term follow-up of cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? J Clin Oncol. 2010;28(4):531–6.

    Article  CAS  PubMed  Google Scholar 

  • Fizazi K, Tjulandin S, Salvioni R, et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy results from an international study. J Clin Oncol. 2001;19:2647–57.

    Article  CAS  PubMed  Google Scholar 

  • Flechon A, Bompas E, Biron P, Droz JP. Management of post-chemotherapy residual masses in advanced seminoma. J Urol. 1979;168:1975–9.

    Article  Google Scholar 

  • Fosså SD, Borge L, Aass N, Johannessen NB, Stenwig AE, Kaalhus O. The treatment of advanced metastatic seminoma: experience in 55 cases. J Clin Oncol. 1987; 5(7):1071–7.

    Article  PubMed  Google Scholar 

  • Friedman EL, Garnick MB, Stomper PC, Mauch PM, Harrington DP, Richie JP. Therapeutic guidelines and results in advanced seminoma. J Clin Oncol. 1985; 3:1325–32.

    Article  CAS  PubMed  Google Scholar 

  • Fujioka T, Nomura K, Okamoto T, Aoki H, Ohhori T, Kubo T. Retroperitoneal lymph node dissection for testicular tumors using the thoracoabdominal approach. Int Surg. 1993;78:154–8.

    CAS  PubMed  Google Scholar 

  • Hahn T, Jacobson L, Einhorn L, et al. Hepatic resection of metastatic testicular carcinoma: a further update. Ann Surg Oncol. 1999;6:640–4.

    Article  CAS  PubMed  Google Scholar 

  • Heidenreich A, Albers P, Hartmann M, Kliesch S, Körhmann KU, Krege S, Lossin P, Weissbach L, German Testicular Cancer Study Group. Complications of primary nerve-sparing lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. J Urol. 2003;169:1710–4.

    Article  PubMed  Google Scholar 

  • Heidenreich A, Ohlmann C, Hegele A, Beyer J. Repeat retroperitoneal lymphadenectomy in advanced testicular cancer. Eur Urol. 2005;47:64–71.

    Article  PubMed  Google Scholar 

  • Heidenreich A, Pfister D, Witthuhn R, Thüer D, Albers P. Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. Eur Urol. 2009;55(1):217–24.

    Article  PubMed  Google Scholar 

  • Heidenreich A, Haidl F, Paffenholz P, Pape C, Neumann U, Pfister D. Surgical management of complex residual masses following systemic chemotherapy for metastatic testicular germ cell tumours. Ann Oncol. 2017;28(2):362–7.

    CAS  PubMed  Google Scholar 

  • Hendry WF, Norman AR, Dearnaley DP, Fisher C, Nicholls J, Huddart RA, Horwich A. Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer. 2002;94:1668–76.

    Article  PubMed  Google Scholar 

  • Herr HW. Does necrosis on frozen-section analysis of a mass after chemotherapy justify a limited retroperitoneal resection in patients with advanced testis cancer? Br J Urol. 1997;80:653–7.

    Article  CAS  PubMed  Google Scholar 

  • Herr HW, Sheinfeld J, Puc HS, Heelan R, Bajorin DF, Mencel P, Bosl GJ, Motzer RJ. Surgery for a post-chemotherapy residual mass in seminoma. J Urol. 1997;157:860–2.

    Article  CAS  PubMed  Google Scholar 

  • Hitchins R, Philip P, Wignall B, et al. Bone disease in testicular and extragonadal germ cell tumours. Br J Cancer. 1988;58:793–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hofmockel G, Gruss A, Theiss M. Chemotherapy in advanced seminoma and the role of postcytostatic retroperitoneal lymph node dissection. Urol Int. 1996;57:38–42.

    Article  CAS  PubMed  Google Scholar 

  • Iida K, Naiki T, Kawai N, et al. Metastasectomy as optimal treatment for late relapsing solitary brain metastasis from testicular germ cell tumor: a case report. BMC Res Notes. 2014;7:865.

    Article  PubMed  PubMed Central  Google Scholar 

  • Jacobsen N, Beck S, Jacobsen L, et al. Is retroperitoneal history predictive of liver histology at concurrent postchemotherapy retroperitoneal lymph node dissection and hepatic resection. J Urol. 2010;184:949–53.

    Article  PubMed  Google Scholar 

  • Johnston P, Beck SD, Cheng L, Masterson TA, Bihrle R, Kesler K, Foster RS. Incidence, histology and management of intraluminal thrombus at post-chemotherapy retroperitoneal lymph node dissection. J Urol. 2013; 190(3):874–8.

    Article  PubMed  Google Scholar 

  • Kamat MR, Kulkarni JN, Tongoankar HB, Ravi R. Value of retroperitoneal lymph node dissection in advanced testicular seminoma. J Surg Oncol. 1992;51:65–7.

    Article  CAS  PubMed  Google Scholar 

  • Kollmannsberger C, Daneshmand S, So A, Chi KN, Murray N, Moore C, Hayes-Lattin B, Nichols C. Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery. J Clin Oncol. 2010;28(4):537–42.

    Article  PubMed  Google Scholar 

  • Krege S, Beyer J, Souchon R, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part I. Eur Urol. 2008;53:478–96.

    Article  PubMed  Google Scholar 

  • McKiernan JM, Motzer RJ, Bajorin DF, Bacik J, Bosl GJ, Sheinfeld J. Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence and outcome. Urology. 2003;62:732–6.

    Article  PubMed  Google Scholar 

  • Mosharafa AA, Foster RS, Leibovich CC, Bihrle R, Johnson C, Donohue JP. Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity? J Urol. 2003;169:2126–8.

    Article  PubMed  Google Scholar 

  • Mosharafa AA, Foster RS, Koch MO, Bihrle R, Donohue JP. Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancer. J Urol. 2004;171:1839–41.

    Article  PubMed  Google Scholar 

  • Oechsle K, Bokemeyer C. Treatment of brain metastases from germ cell tumors. Hematol Oncol Clin North Am. 2011;25:605–13.

    Article  PubMed  Google Scholar 

  • Oldenburg J, Fosså SD, Nuver J, Heidenreich A, Schmoll HJ, Bokemeyer C, Horwich A, Beyer J, Kataja V, ESMO Guidelines Working Group. Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi125–32.

    Article  PubMed  Google Scholar 

  • Pfister D, Busch J, Winter C, Albers P, Schrader M, Dieckmann KP, Krege S, Schmelz H, Heidenreich A. Pathohistological findings in patients with nonseminomatous germ cell tumours who undergo postchemotherapy retroperitoneal lymph node dissection for small tumours. J Urol. 2011;185:e334, AUA Abstract # 830

    Article  Google Scholar 

  • Pfister D, Porres D, Matveev V, Heidenreich A. Reduced morbidity in resection of residual tumors after chemotherapy for seminoma. Urologe A. 2015;54(10): 1402–6.

    Article  CAS  PubMed  Google Scholar 

  • Puc HS, Heelan R, Mazumdar M, Herr H, Sheinfeld JE, Vlasmis V, Bajorin DF, Bosl GJ, Mencel P, Motzer RJ. Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan Kettering Cancer Center. J Clin Oncol. 1996;14:454–60.

    Article  CAS  PubMed  Google Scholar 

  • Qvist HL, Fossa SD, Ous S, Hoie J, Stenwig AE, Giercksky KE. Post-chemotherapy tumor residuals in patients with advanced nonseminomatous testicular cancer. Is it necessary to resect all residual masses? J Urol. 1991;145:300–2.

    Article  CAS  PubMed  Google Scholar 

  • Rabbani F, Goldenberg SL, Gleave ME, Paterson RF, Murray N, Sullivan LD. Retroperitoneal lymphadenectomy for post-chemotherapy residual masses: is a modified dissection and resection of the residual mass sufficient? Br J Urol. 1998;81:295–300.

    Article  CAS  PubMed  Google Scholar 

  • Ravi R, Rao RR, Shanta V. Integrated approach to the management of patients with advanced germ cell tumors of the testis. J Surg Oncol. 1994;55(1):47–51.

    Article  CAS  PubMed  Google Scholar 

  • Rivoire M, Elias D, De Cian F, et al. Multimodality treatment of patients with liver metastases from germ cell tumours. Cancer. 2001;92:578–87.

    Article  CAS  PubMed  Google Scholar 

  • Schultz SM, Einhorn LH, Conces DJ, Williams SD, Loehrer PJ. Management of postchemotherapy residual mass in patients with advanced seminoma: Indiana University experience. J Clin Oncol. 1989;7:1497–503.

    Article  CAS  PubMed  Google Scholar 

  • Sexton WJ, Wood CG, Kim R, Pisters LL. Repeat retroperitoneal lymph node dissection for metastatic testis cancer. J Urol. 2003;169:1353–6.

    Article  PubMed  Google Scholar 

  • Skinner DG, Melamud A, Lieskovsky G. Complications of thoracoabdominal retroperitoneal lymph node dissection. J Urol. 1982;127:1107–10.

    Article  CAS  PubMed  Google Scholar 

  • Sonneveld DJ, Sleijfer DT, Koops HS, Keemers-Gels ME, Molenaar WM, Hoekstra HJ. Mature teratoma identified after postchemotherapy surgery in patients with disseminated nonseminomatous testicular germ cell tumors: a plea for an aggressive surgical approach. Cancer. 1998;82:1343–51.

    Article  CAS  PubMed  Google Scholar 

  • Uygun K, Karagol H, Kocak Z, et al. Isolated bone metastasis in testicular germ cell tumors: a case report and review of the literature. Onkologie. 2006;29:93–5.

    PubMed  Google Scholar 

  • Vallier C, Savoie PH, Delpero JR, Bladou F, Gravis G, Salem N, Rossi D, Walz J. External validation of the Heidenreich criteria for patient selection for unilateral or bilateral retroperitoneal lymph node dissection for post-chemotherapy residual masses of testicular cancer. World J Urol. 2014;32(6):1573–8.

    Article  CAS  PubMed  Google Scholar 

  • Waples MJ, Messing EM. Redo retroperitoneal lymphadenectomy for germ cell tumor. Urology. 1993;42:1–4.

    Article  Google Scholar 

  • Winter C, Pfister D, Busch J, Bingöl C, Ranft U, Schrader M, Dieckmann KP, Heidenreich A, Albers P. Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group. Eur Urol. 2012;61(2):403–9.

    Article  PubMed  Google Scholar 

  • Woldu SL, Matulay JT, Clinton TN, Singla N, Krabbe LM, Hutchinson RC, Sagalowsky A, Lotan Y, Margulis V, Bagrodia A. Impact of hospital case volume on testicular cancer outcomes and practice patterns. Urol Oncol. 2018;36(14):e7–15.

    Google Scholar 

  • Wood DP, Herr HW, Heller G, Vlamis V, Sogani PC, Motzer RJ, Fair WR, Bosl GJ. Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors. J Urol. 1992;148: 1812–6.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Urologic Oncology, Robot-assisted and Specialized Urologic Surgery, University Hospital Cologne, Köln, Germany

    Axel Heidenreich & David Pfister

Authors
  1. Axel Heidenreich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Pfister
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Axel Heidenreich .

Editor information

Editors and Affiliations

  1. Urologie, Univ Lübeck, Lübeck, Schleswig-Holstein, Germany

    Axel Merseburger

  2. Dept. of Urology, University of Regensburg St. Josef Medical Centre, Regensburg, Germany

    Maximilian Burger

Section Editor information

  1. Universitätsklinikum Rostock , Urologische Klinik und Poliklinik, Rostock, Germany

    Chris Protzel

  2. Division of Oncological Urology, Department of Urology, University of Köln, Köln, Germany

    Axel Heidenreich

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Heidenreich, A., Pfister, D. (2019). Postchemotherapy Retroperitoneal Lymph Node Dissection in Advanced Germ Cell Tumors of the Testis. In: Merseburger, A., Burger, M. (eds) Urologic Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-42603-7_9-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-42603-7_9-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-42603-7

  • Online ISBN: 978-3-319-42603-7

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation